All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
During the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the MPN Hub was pleased to speak to Helen Ajufo, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What implications might the PERSIST-2 landmark overall survival (OS) analysis data have on the use of pacritinib in myelofibrosis?
What implications might the PERSIST-2 landmark OS analysis data have on the use of pacritinib in MF?
In this interview, Ajufo shares insights on the latest analysis from the PERSIST-2 trial on spleen reduction as a predictor of OS in pacritinib-treated myelofibrosis. Ajufo discusses the OS data, stratified by patient platelet count and spleen volume reduction achieved, making comparisons with corresponding data from the control arm of best available therapy. This interview concludes with a look at the future application of pacritinib in myelofibrosis.
For more information on pacritinib and the PERSIST-2 trail, visit our previous coverage from ASCO and EBMT.
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox